leisure time -WSS

leisure time

author：explore 2025-09-04 05:35:56 - browse：73

Is Wegovy the future of cardiology? Can Novo Nordisk ever make enough of it? And will there ever be an Apple of pharma?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. In the wake of a massively important clinical trial of Novo Nordisk’s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don’t know about data that could change the practice of medicine. Then, Mizuho Securities biotech strategist Jared Holz calls in to discuss whether explosive popularity of obesity treatments could help create the first trillion-dollar drug company.

For more on what we cover, here’s the news on the Wegovy study; here’s more on its implications; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Why Novartis is going to walk from its acquisition of MorphoSys

WSS

Longer MASH drug regimen improved liver, Akero study finds

Surgery pushed Ben Carson to fame

340B reform proposal comes out of Senate working group

$1 billion proposal to grow Boston, Massachusetts biotech

Longer MASH drug regimen improved liver, Akero study finds

Fetal cell organoids grown from amniotic fluid, study finds

hotspot

leisure time

hotspot

Hollywood unions extend contract negotiations for actors

Florida health officials providing scant details on measles cases

ChatGPT in medicine: STAT answers readers' burning questions

Streamlined flu vaccines recommended by FDA advisory panel

Cancer drug shortages should be causing more outrage

A new approach to psychiatric drug development

Activists slam private health insurers over coverage restrictions

Bernie brings in new pharma CEOs to talk drug prices

Medicare details structure of new drug price negotiation program

AI gets buy

explore

AstraZeneca stays mum on Medicare drug pricing negotiations

Gene therapy for Afghan refugees’ infant will be fully covered

Families look for replacement for GSK asthma drug Flovent

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Cano Health’s bankruptcy is a warning for Medicare Advantage

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

hotspot

leisure time

focus

focus